Halozyme Reports Second Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Halozyme Reports Second Quarter 2018 Results

Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital

August 8, 2018 6:59 AM EDT

BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform rating.

Analsyt Do Kim commented, "We raise our target to $21 from $19, as our probability of success for PEGPH20 in pancreatic cancer increases to 70% from 65%, following positive... More

Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c

August 7, 2018 4:57 PM EDT

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.16), $0.06 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $30.09 million.

GUIDANCE:

Halozyme Therapeutics sees FY2018 revenue of $125-135 million, versus the consensus of... More